Suchergebnisse - "Usmani, Saad Z"

PubPharm (308)

91

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

enthalten in: EJHaem | 2022

von Martin, T. | Krishnan, A. | Yong, K. | +16

92

Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

enthalten in: Blood | 2022

von Cavo, M. | San-Miguel, J. | Usmani, S. | +24

CommentIn: Blood. 2022 Feb 10;139(6):799-802. - PMID 35142848

93

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

enthalten in: Blood | 2022

von San-Miguel, J. | Avet-Loiseau, H. | Paiva, B. | +24

CommentIn: Blood. 2022 Jan 27;139(4):469-471. - PMID 35084473

94

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical drug investigation | 2022

von Weisel, K. | Martin, T. | Krishnan, A. | +14

95

Gene Expression Profiling in Multiple Myeloma : Redefining the Paradigm of Risk-Adapted Treatment

enthalten in: Frontiers in oncology | 2022

von Cerchione, C. | Usmani, S. | Stewart, A. | +7

96

Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

enthalten in: Bone marrow transplantation | 2022

von Pasvolsky, O. | Yeshurun, M. | Fraser, R. | +27

97

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : updated outcomes from a randomised, multicentre, open-label, phase 3 study

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Quach, H. | Mateos, M. | +15

CommentIn: Lancet Oncol. 2022 Mar;23(3):e97. - PMID 35240098

98

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

enthalten in: British Journal of Haematology | 2022

von Landgren, O. | Weisel, K. | Rosinol, L. | +9

99

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

enthalten in: eJHaem | 2022

von Martin, T. | Krishnan, A. | Yong, K. | +16

100

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

enthalten in: Leukemia | 2021

von Usmani, S. | Karanes, C. | Bensinger, W. | +11